The announcement of FDA alignment on an abbreviated pathway for potential approval, coupled with EMA PRIME eligibility for ST-920, is a significant positive development for Sangamo Therapeutics. This regulatory progress not only validates the potential of ST-920 in treating Fabry disease but also enhances the company's credibility and prospects in the biotech industry. Such regulatory milestones are typically viewed positively by investors, as they represent critical steps towards commercialization and revenue generation from the treatment.